Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life
Background and aims: Severe asthma is burdened by frequent exacerbations and use of oral corticosteroids (OCS) which worsen patients’ health and increase healthcare spending. Aim of this study was to assess the clinical and economic effect of adding mepolizumab (MEP) for the treatment of these patie...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-02-01
|
| Series: | World Allergy Organization Journal |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S193945512100003X |
| _version_ | 1818742181977915392 |
|---|---|
| author | Diego Bagnasco Massimiliano Povero Lorenzo Pradelli Luisa Brussino Giovanni Rolla Marco Caminati Francesco Menzella Enrico Heffler Giorgio Walter Canonica Pierluigi Paggiaro Gianenrico Senna Manlio Milanese Carlo Lombardi Caterina Bucca Andrea Manfredi Rikki Frank Canevari Giovanni Passalacqua Gabriella Guarnieri Vincenzo Patella Foschino Barbaro Maria Pia Elisiana Carpagnano Anna del Colle Giulia Scioscia Pelaia Gerolamo Pierluigi Paggiaro Manuela Latorre Francesca Puggioni Francesca Racca Elisabetta Favero Sandra Iannacone Eleonora Savi Marcello Montagni Gianna Camiciottoli Chiara Allegrini Giuseppe Spadaro Caterina Detoraki Carla Galeone Patrizia Ruggiero Monna Rita Yacoub Alvise Berti Gisella Colombo Nicola Scichilone Carmen Durante Maria Teresa Costantino Chiara Roncallo Mariachiara Braschi Francesco Blasi Alice D'Adda Erminia Ridolo Massimo Triggiani Roberta Parente D'Amato Maria Maria Vittoria Verrillo Zappa Maria Cristina Marianna Lilli Nunzio Crimi Marco Bonavia Angelo Guido Corsico Amelia Grosso Stefano Del Giacco Margherita Deidda Luisa Ricciardi Stefania Isola Francesca Cicero Giuliana Amato Federica Vita Antonio Spanevello Patrizia Pignatti Francesca Cherubino Dina Visca Eleonora Aletti Fabio Luigi Massimo Ricciardolo Vitina Maria Anna Carriero Francesca Bertolini Pierachille Santus Roberta Barlassina Andrea Airoldi Giuseppe Guida Nucera Eleonora Arianna Aruanno Angela Rizzi Cristiano Caruso Stefania Colantuono Alessandra Arcolaci Andrea Vianello Fulvia Chieco Bianchi Maria Rita Marchi Stefano Centanni Simone Luraschi Silvia Ruggeri Rocco Rinaldo Elena Parazzini Cecilia Calabrese Martina Flora Lorenzo Cosmi Linda Di Pietro Enrico Maggi Laura Pini Luigi Macchia Danilo Di Bona Luca Richeldi Carola Condoluci Leonello Fuso Matteo Bonini Alessandro Farsi Giulia Carli Paolo Montuschi Giuseppe Santini Maria Elisabetta Conte Elisa Turchet Carlo Barbetta Francesco Mazza Simona D'Alo Stefano Pucci Maria Filomena Caiaffa Elena Minenna Luciana D'Elia Carlo Pasculli Vittorio Viviano Paolo Tarsia Joyce Rolo Mariacarmela Di Proietto Salvatore Lo Cicero Mariacarmela Di Proietto |
| author_facet | Diego Bagnasco Massimiliano Povero Lorenzo Pradelli Luisa Brussino Giovanni Rolla Marco Caminati Francesco Menzella Enrico Heffler Giorgio Walter Canonica Pierluigi Paggiaro Gianenrico Senna Manlio Milanese Carlo Lombardi Caterina Bucca Andrea Manfredi Rikki Frank Canevari Giovanni Passalacqua Gabriella Guarnieri Vincenzo Patella Foschino Barbaro Maria Pia Elisiana Carpagnano Anna del Colle Giulia Scioscia Pelaia Gerolamo Pierluigi Paggiaro Manuela Latorre Francesca Puggioni Francesca Racca Elisabetta Favero Sandra Iannacone Eleonora Savi Marcello Montagni Gianna Camiciottoli Chiara Allegrini Giuseppe Spadaro Caterina Detoraki Carla Galeone Patrizia Ruggiero Monna Rita Yacoub Alvise Berti Gisella Colombo Nicola Scichilone Carmen Durante Maria Teresa Costantino Chiara Roncallo Mariachiara Braschi Francesco Blasi Alice D'Adda Erminia Ridolo Massimo Triggiani Roberta Parente D'Amato Maria Maria Vittoria Verrillo Zappa Maria Cristina Marianna Lilli Nunzio Crimi Marco Bonavia Angelo Guido Corsico Amelia Grosso Stefano Del Giacco Margherita Deidda Luisa Ricciardi Stefania Isola Francesca Cicero Giuliana Amato Federica Vita Antonio Spanevello Patrizia Pignatti Francesca Cherubino Dina Visca Eleonora Aletti Fabio Luigi Massimo Ricciardolo Vitina Maria Anna Carriero Francesca Bertolini Pierachille Santus Roberta Barlassina Andrea Airoldi Giuseppe Guida Nucera Eleonora Arianna Aruanno Angela Rizzi Cristiano Caruso Stefania Colantuono Alessandra Arcolaci Andrea Vianello Fulvia Chieco Bianchi Maria Rita Marchi Stefano Centanni Simone Luraschi Silvia Ruggeri Rocco Rinaldo Elena Parazzini Cecilia Calabrese Martina Flora Lorenzo Cosmi Linda Di Pietro Enrico Maggi Laura Pini Luigi Macchia Danilo Di Bona Luca Richeldi Carola Condoluci Leonello Fuso Matteo Bonini Alessandro Farsi Giulia Carli Paolo Montuschi Giuseppe Santini Maria Elisabetta Conte Elisa Turchet Carlo Barbetta Francesco Mazza Simona D'Alo Stefano Pucci Maria Filomena Caiaffa Elena Minenna Luciana D'Elia Carlo Pasculli Vittorio Viviano Paolo Tarsia Joyce Rolo Mariacarmela Di Proietto Salvatore Lo Cicero Mariacarmela Di Proietto |
| author_sort | Diego Bagnasco |
| collection | DOAJ |
| description | Background and aims: Severe asthma is burdened by frequent exacerbations and use of oral corticosteroids (OCS) which worsen patients’ health and increase healthcare spending. Aim of this study was to assess the clinical and economic effect of adding mepolizumab (MEP) for the treatment of these patients. Methods: Patients >18 years old, referred to 8 asthma clinics, starting MEP between May 2017 and December 2018, were enrolled and followed-up for 12 months. Information in the 12 months before mepolizumab were collected retrospectively. The evaluation parameters included: OCS use, number of exacerbations/hospitalizations, concomitant therapies, comorbidity, and annual number of working days lost due to the disease. The primary objective was to compare the annual total cost per patient pre- and post-MEP. Secondary outcomes included rates of exacerbations and number of OCS-dependent patients. Results: 106 patients were enrolled in the study: 46 male, median age 58 years. Mean annual cost pre- and post-MEP (cost of biologic excluded) was €3996 and €1,527, respectively. Total savings due to MEP resulted in €2469 (95%CI 1945–2993), 62% due to exacerbations reduction and 33% due to productivity increase. Such savings could fund about 22% of the total cost of MEP for one year. The introduction of MEP induced a clinical benefit by reducing both OCS-dependent patients (OR = 0.12, 95%CI 0.06–0.23) and exacerbation rate (RR = 0.19, 95%CI 0.15–0.24). Conclusions: Patients with severe eosinophilic asthma experienced a clinical benefit in asthma control adding MEP to standard therapy. Biologic therapy can be, partially, funded by the savings produced by patients’ improvement. |
| first_indexed | 2024-12-18T02:08:27Z |
| format | Article |
| id | doaj.art-a6b155b11471426182b50e5cdb6d37c8 |
| institution | Directory Open Access Journal |
| issn | 1939-4551 |
| language | English |
| last_indexed | 2024-12-18T02:08:27Z |
| publishDate | 2021-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | World Allergy Organization Journal |
| spelling | doaj.art-a6b155b11471426182b50e5cdb6d37c82022-12-21T21:24:33ZengElsevierWorld Allergy Organization Journal1939-45512021-02-01142100509Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real lifeDiego Bagnasco0Massimiliano Povero1Lorenzo Pradelli2Luisa Brussino3Giovanni Rolla4Marco Caminati5Francesco Menzella6Enrico Heffler7Giorgio Walter Canonica8Pierluigi Paggiaro9Gianenrico Senna10Manlio Milanese11Carlo Lombardi12Caterina Bucca13Andrea Manfredi14Rikki Frank Canevari15Giovanni Passalacqua16Gabriella GuarnieriVincenzo PatellaFoschino Barbaro Maria PiaElisiana CarpagnanoAnna del ColleGiulia SciosciaPelaia GerolamoPierluigi PaggiaroManuela LatorreFrancesca PuggioniFrancesca RaccaElisabetta FaveroSandra IannaconeEleonora SaviMarcello MontagniGianna CamiciottoliChiara AllegriniGiuseppe SpadaroCaterina DetorakiCarla GaleonePatrizia RuggieroMonna Rita YacoubAlvise BertiGisella ColomboNicola ScichiloneCarmen DuranteMaria Teresa CostantinoChiara RoncalloMariachiara BraschiFrancesco BlasiAlice D'AddaErminia RidoloMassimo TriggianiRoberta ParenteD'Amato MariaMaria Vittoria VerrilloZappa Maria CristinaMarianna LilliNunzio CrimiMarco BonaviaAngelo Guido CorsicoAmelia GrossoStefano Del GiaccoMargherita DeiddaLuisa RicciardiStefania IsolaFrancesca CiceroGiuliana AmatoFederica VitaAntonio SpanevelloPatrizia PignattiFrancesca CherubinoDina ViscaEleonora AlettiFabio Luigi Massimo RicciardoloVitina Maria Anna CarrieroFrancesca BertoliniPierachille SantusRoberta BarlassinaAndrea AiroldiGiuseppe GuidaNucera EleonoraArianna AruannoAngela RizziCristiano CarusoStefania ColantuonoAlessandra ArcolaciAndrea VianelloFulvia Chieco BianchiMaria Rita MarchiStefano CentanniSimone LuraschiSilvia RuggeriRocco RinaldoElena ParazziniCecilia CalabreseMartina FloraLorenzo CosmiLinda Di PietroEnrico MaggiLaura PiniLuigi MacchiaDanilo Di BonaLuca RicheldiCarola CondoluciLeonello FusoMatteo BoniniAlessandro FarsiGiulia CarliPaolo MontuschiGiuseppe SantiniMaria Elisabetta ConteElisa TurchetCarlo BarbettaFrancesco MazzaSimona D'AloStefano PucciMaria Filomena CaiaffaElena MinennaLuciana D'EliaCarlo PasculliVittorio VivianoPaolo TarsiaJoyce RoloMariacarmela Di ProiettoSalvatore Lo CiceroMariacarmela Di ProiettoAllergy and Respiratory Diseases, IRCCS Policlinico San Martino – University of Genoa, Italy; Corresponding author. Allergy and Respiratory Diseases, IRCCS Policlinico San Martino-University of Genoa, L.go R.Benzi 10, 16132, Genoa, ItalyAdRes, Turin, ItalyAdRes, Turin, ItalyMauriziano Hospital of Torino, Department of Medical Science, University of Torino, ItalyMauriziano Hospital of Torino, Department of Medical Science, University of Torino, ItalyAsthma Center and Allergy Unit, Verona University and General Hospital, Department of Medicine, University of Verona, Verona, ItalyAzienda USL di Reggio Emilia-IRCSS, Santa Maria Nuova Hospital- Pneumology Unit, Reggio Emilia, ItalyPersonalized Medicine, Asthma and Allergy - Humanitas Clinical and Research Center – IRCCS – Rozzano (Milan), Italy; Department of Biomedical Sciences - Humanitas University - Pieve Emanuele (MI), ItalyPersonalized Medicine, Asthma and Allergy - Humanitas Clinical and Research Center – IRCCS – Rozzano (Milan), Italy; Department of Biomedical Sciences - Humanitas University - Pieve Emanuele (MI), ItalyDepartment of Surgery, Medicine, Molecular Biology and Critical Care, University of Pisa, ItalyAsthma Center and Allergy Unit, Verona University and General Hospital, Department of Medicine, University of Verona, Verona, ItalyDivision of Pneumology, S.Corona Hospital, Pietra Ligure, ItalyDepartmental Unit of Allergology & Respiratory Diseases, Fondazione Poliambulanza, Brescia, ItalyAzienda Ospedale-Università Città della Salute e della Scienza, S.C. Pneumologia, Dept. of Medical Sciences University of Turin, TurinAllergy and Respiratory Diseases, IRCCS Policlinico San Martino – University of Genoa, ItalyDepartment of Surgical Sciences and Integrated Diagnostics (DISC), University of Genoa, Genoa, Italy, IRCCS Ospedale Policlinico San Martino, Genoa, ItalyAllergy and Respiratory Diseases, IRCCS Policlinico San Martino – University of Genoa, ItalyBackground and aims: Severe asthma is burdened by frequent exacerbations and use of oral corticosteroids (OCS) which worsen patients’ health and increase healthcare spending. Aim of this study was to assess the clinical and economic effect of adding mepolizumab (MEP) for the treatment of these patients. Methods: Patients >18 years old, referred to 8 asthma clinics, starting MEP between May 2017 and December 2018, were enrolled and followed-up for 12 months. Information in the 12 months before mepolizumab were collected retrospectively. The evaluation parameters included: OCS use, number of exacerbations/hospitalizations, concomitant therapies, comorbidity, and annual number of working days lost due to the disease. The primary objective was to compare the annual total cost per patient pre- and post-MEP. Secondary outcomes included rates of exacerbations and number of OCS-dependent patients. Results: 106 patients were enrolled in the study: 46 male, median age 58 years. Mean annual cost pre- and post-MEP (cost of biologic excluded) was €3996 and €1,527, respectively. Total savings due to MEP resulted in €2469 (95%CI 1945–2993), 62% due to exacerbations reduction and 33% due to productivity increase. Such savings could fund about 22% of the total cost of MEP for one year. The introduction of MEP induced a clinical benefit by reducing both OCS-dependent patients (OR = 0.12, 95%CI 0.06–0.23) and exacerbation rate (RR = 0.19, 95%CI 0.15–0.24). Conclusions: Patients with severe eosinophilic asthma experienced a clinical benefit in asthma control adding MEP to standard therapy. Biologic therapy can be, partially, funded by the savings produced by patients’ improvement.http://www.sciencedirect.com/science/article/pii/S193945512100003XSevere asthmaMepolizumabAnti IL-5PharmacoeconomicsOCSComorbidities |
| spellingShingle | Diego Bagnasco Massimiliano Povero Lorenzo Pradelli Luisa Brussino Giovanni Rolla Marco Caminati Francesco Menzella Enrico Heffler Giorgio Walter Canonica Pierluigi Paggiaro Gianenrico Senna Manlio Milanese Carlo Lombardi Caterina Bucca Andrea Manfredi Rikki Frank Canevari Giovanni Passalacqua Gabriella Guarnieri Vincenzo Patella Foschino Barbaro Maria Pia Elisiana Carpagnano Anna del Colle Giulia Scioscia Pelaia Gerolamo Pierluigi Paggiaro Manuela Latorre Francesca Puggioni Francesca Racca Elisabetta Favero Sandra Iannacone Eleonora Savi Marcello Montagni Gianna Camiciottoli Chiara Allegrini Giuseppe Spadaro Caterina Detoraki Carla Galeone Patrizia Ruggiero Monna Rita Yacoub Alvise Berti Gisella Colombo Nicola Scichilone Carmen Durante Maria Teresa Costantino Chiara Roncallo Mariachiara Braschi Francesco Blasi Alice D'Adda Erminia Ridolo Massimo Triggiani Roberta Parente D'Amato Maria Maria Vittoria Verrillo Zappa Maria Cristina Marianna Lilli Nunzio Crimi Marco Bonavia Angelo Guido Corsico Amelia Grosso Stefano Del Giacco Margherita Deidda Luisa Ricciardi Stefania Isola Francesca Cicero Giuliana Amato Federica Vita Antonio Spanevello Patrizia Pignatti Francesca Cherubino Dina Visca Eleonora Aletti Fabio Luigi Massimo Ricciardolo Vitina Maria Anna Carriero Francesca Bertolini Pierachille Santus Roberta Barlassina Andrea Airoldi Giuseppe Guida Nucera Eleonora Arianna Aruanno Angela Rizzi Cristiano Caruso Stefania Colantuono Alessandra Arcolaci Andrea Vianello Fulvia Chieco Bianchi Maria Rita Marchi Stefano Centanni Simone Luraschi Silvia Ruggeri Rocco Rinaldo Elena Parazzini Cecilia Calabrese Martina Flora Lorenzo Cosmi Linda Di Pietro Enrico Maggi Laura Pini Luigi Macchia Danilo Di Bona Luca Richeldi Carola Condoluci Leonello Fuso Matteo Bonini Alessandro Farsi Giulia Carli Paolo Montuschi Giuseppe Santini Maria Elisabetta Conte Elisa Turchet Carlo Barbetta Francesco Mazza Simona D'Alo Stefano Pucci Maria Filomena Caiaffa Elena Minenna Luciana D'Elia Carlo Pasculli Vittorio Viviano Paolo Tarsia Joyce Rolo Mariacarmela Di Proietto Salvatore Lo Cicero Mariacarmela Di Proietto Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life World Allergy Organization Journal Severe asthma Mepolizumab Anti IL-5 Pharmacoeconomics OCS Comorbidities |
| title | Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life |
| title_full | Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life |
| title_fullStr | Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life |
| title_full_unstemmed | Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life |
| title_short | Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life |
| title_sort | economic impact of mepolizumab in uncontrolled severe eosinophilic asthma in real life |
| topic | Severe asthma Mepolizumab Anti IL-5 Pharmacoeconomics OCS Comorbidities |
| url | http://www.sciencedirect.com/science/article/pii/S193945512100003X |
| work_keys_str_mv | AT diegobagnasco economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT massimilianopovero economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT lorenzopradelli economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT luisabrussino economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT giovannirolla economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT marcocaminati economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT francescomenzella economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT enricoheffler economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT giorgiowaltercanonica economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT pierluigipaggiaro economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT gianenricosenna economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT manliomilanese economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT carlolombardi economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT caterinabucca economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT andreamanfredi economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT rikkifrankcanevari economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT giovannipassalacqua economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT gabriellaguarnieri economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT vincenzopatella economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT foschinobarbaromariapia economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT elisianacarpagnano economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT annadelcolle economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT giuliascioscia economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT pelaiagerolamo economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT pierluigipaggiaro economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT manuelalatorre economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT francescapuggioni economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT francescaracca economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT elisabettafavero economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT sandraiannacone economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT eleonorasavi economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT marcellomontagni economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT giannacamiciottoli economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT chiaraallegrini economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT giuseppespadaro economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT caterinadetoraki economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT carlagaleone economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT patriziaruggiero economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT monnaritayacoub economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT alviseberti economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT gisellacolombo economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT nicolascichilone economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT carmendurante economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT mariateresacostantino economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT chiararoncallo economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT mariachiarabraschi economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT francescoblasi economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT alicedadda economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT erminiaridolo economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT massimotriggiani economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT robertaparente economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT damatomaria economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT mariavittoriaverrillo economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT zappamariacristina economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT mariannalilli economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT nunziocrimi economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT marcobonavia economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT angeloguidocorsico economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT ameliagrosso economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT stefanodelgiacco economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT margheritadeidda economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT luisaricciardi economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT stefaniaisola economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT francescacicero economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT giulianaamato economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT federicavita economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT antoniospanevello economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT patriziapignatti economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT francescacherubino economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT dinavisca economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT eleonoraaletti economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT fabioluigimassimoricciardolo economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT vitinamariaannacarriero economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT francescabertolini economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT pierachillesantus economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT robertabarlassina economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT andreaairoldi economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT giuseppeguida economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT nuceraeleonora economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT ariannaaruanno economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT angelarizzi economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT cristianocaruso economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT stefaniacolantuono economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT alessandraarcolaci economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT andreavianello economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT fulviachiecobianchi economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT mariaritamarchi economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT stefanocentanni economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT simoneluraschi economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT silviaruggeri economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT roccorinaldo economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT elenaparazzini economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT ceciliacalabrese economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT martinaflora economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT lorenzocosmi economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT lindadipietro economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT enricomaggi economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT laurapini economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT luigimacchia economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT danilodibona economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT lucaricheldi economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT carolacondoluci economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT leonellofuso economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT matteobonini economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT alessandrofarsi economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT giuliacarli economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT paolomontuschi economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT giuseppesantini economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT mariaelisabettaconte economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT elisaturchet economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT carlobarbetta economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT francescomazza economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT simonadalo economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT stefanopucci economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT mariafilomenacaiaffa economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT elenaminenna economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT lucianadelia economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT carlopasculli economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT vittorioviviano economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT paolotarsia economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT joycerolo economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT mariacarmeladiproietto economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT salvatorelocicero economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife AT mariacarmeladiproietto economicimpactofmepolizumabinuncontrolledsevereeosinophilicasthmainreallife |